Analyst Etzer Darout of BMO Capital maintained a Buy rating on AstraZeneca (AZN – Research Report), retaining the price target of $89.00.
AstraZeneca said on Tuesday that it does not comment on speculative media reports, in response to a sharp drop in its share ...
Chinese authorities detained AstraZeneca employees amid a probe into data privacy breaches and unlicensed drug sales, stock ...
Britain's benchmark FTSE 100 edged lower on Tuesday, hurt by AstraZeneca's fall on a potential China probe, while investors ...
Bullish option flow detected in AstraZeneca (AZN) with 5,692 calls trading, 5x expected, and implied vol increasing almost 3 points to 33.14%.
AstraZeneca PLC shed £15 billion in market capitalization on Tuesday, after investors were underwhelmed by early data from a ...
AstraZeneca said on Monday its experimental weight-loss pill, licensed from China's Eccogene, was safe and tolerable in an ...